Home/Filings/4/0001535610-14-000051
4//SEC Filing

Celsus Therapeutics Plc. 4

Accession 0001535610-14-000051

$AKTXCIK 0001541157operating

Filed

Mar 26, 8:00 PM ET

Accepted

Mar 27, 4:15 PM ET

Size

13.6 KB

Accession

0001535610-14-000051

Insider Transaction Report

Form 4
Period: 2014-03-25
Transactions
  • Purchase

    Common Stock

    2014-03-26$6.65/sh+13,300$88,445657,044 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-25$6.90/sh+303$2,091642,844 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-26$6.86/sh+900$6,174643,744 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-27$6.61/sh+1,700$11,237658,744 total(indirect: See Footnotes)
Transactions
  • Purchase

    Common Stock

    2014-03-25$6.90/sh+303$2,091642,844 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-27$6.61/sh+1,700$11,237658,744 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-26$6.86/sh+900$6,174643,744 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-26$6.65/sh+13,300$88,445657,044 total(indirect: See Footnotes)
Mintz Hal
10% Owner
Transactions
  • Purchase

    Common Stock

    2014-03-25$6.90/sh+303$2,091642,844 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-26$6.86/sh+900$6,174643,744 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-26$6.65/sh+13,300$88,445657,044 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-27$6.61/sh+1,700$11,237658,744 total(indirect: See Footnotes)
Footnotes (2)
  • [F1]This Form 4 is being filed by Sabby Healthcare Volatility Master Fund, Ltd. ("SHVMF"), Sabby Management, LLC ("Advisor") and Hal Mintz. The Advisor is the investment manager of SHVMF. Mr. Mintz is the manager of the Advisor.
  • [F2]The amounts reported herein reflect the entire amount of Issuer's securities held by SHVMF as of each transaction date. Each of the Advisor and Mr. Mintz disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934 ("Section 16"), beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the Advisor or Mr. Mintz is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Issuer

Celsus Therapeutics Plc.

CIK 0001541157

Entity typeoperating
IncorporatedUnited Kingdom

Related Parties

1
  • filerCIK 0001541157

Filing Metadata

Form type
4
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 4:15 PM ET
Size
13.6 KB